Mitsubishi Tanabe Pharma

Akebia Therapeutics Inc (NASDAQ: AKBA) has announced a partnership with Mitsubishi Tanabe Pharma on development of vadadustat. The deal could be worth up to $350 million for Akebia. Akebia CEO John Butler told Benzinga that the company is pleased with both the terms of the deal and the partner....